Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).

作者：Gini F. Fleming, Katherine Kurnit, Meredith Pelster, Pamela N. Münster, Raymond Wadlow, Shigehiro Koganemaru, Chiyoe Kitagawa, Takako Eguchi Nakajima, Yuta Maruki, Ruth Perets, Akosua Badu-Nkansah, Martha Blaney, Manal Mehibel, Pin Li, Marjilla Seddiq, Anna Shurshalina, Omar N. Al Yacoub, Michael Charles Burns, Shigehisa Kitano · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.16_suppl.5514 · 被引用次数：2 · 研究领域：HER2/EGFR in Cancer Research、Liver physiology and pathology、Ovarian cancer diagnosis and treatment

5514 Background: c-Met protein is expressed in several tumor types, including PROC, and is linked with poor clinical outcomes. Temab-A comprises a c-Met protein-targeting antibody conjugated to a topoisomerase 1 inhibitor. Phase 1 studies evaluating Temab-A monotherapy in solid tumors showed antitumor activity and a manageable safety profile (NCT05029882, NCT06084481). Here, we report on the efficacy and safety of Temab-A in PROC. Methods: This phase 1, open-label basket study (NCT06084481) enrolled patients (pts) ≥18 years with histologically/cytologically confirmed recurrent PROC, with Eastern Cooperative Oncology Group performance score ≤1. Pts must have had measurable disease per investigator-assessed RECIST v1.1 criteria, have had platinum-resistant disease, and have received ≥1 but ≤5 prior lines of systemic therapy, with ≤2 prior therapies since the development of platinum resistance. Pts received Temab-A at 2.4 mg/kg every 3 weeks. Primary endpoints were safety and efficacy. Results: As of Sept. 11, 2025, 41 pts with PROC received Temab-A. Tumor histology included serous carcinoma (n=26), clear cell carcinoma (n=7), and other rare histologies (n=8). The median age was 64 years (range 43–89), and the median number of prior lines of systemic therapy was 3 (range 1–6). Median follow-up was 5.1 months. Objective response rate (ORR) was 37%. Duration of response, progression-free survival, and overall survival were immature at data cutoff. Efficacy data are shown in the Ta...